Taizhou Dachen Pharmaceuticals Co. Ltd

Established in 2017, Taizhou Dachen Pharmaceutical was designed and built to meet GMP guidelines, integrating research development and production of APIs and intermediates. The gross value of annual output is about 400 million yuan. As the National High-Tech Enterprise, the company's key products are predominantly demanded in Europe, Southeast Asia, South America, etc.